February 23, 2017 / 1:22 PM / 6 months ago

BRIEF-Fibrocell announces dosing of first patient in phase I/II clinical trial of FCX-007 gene therapy

Feb 23 (Reuters) - Fibrocell Science Inc:

* Fibrocell announces dosing of first patient in phase i/ii clinical trial of fcx-007 gene therapy for treatment of recessive dystrophic epidermolysis bullosa

* Fibrocell Science Inc - six adult patients are targeted for phase I portion of trial

* Fibrocell Science Inc - says results of phase i portion of this trial are expected in q3 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below